Liquidia Technologies, Inc. (LQDA) shares rallied 5.7% in the last trading session to close at $13.62. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.7% gain over the past four weeks.
The stock price rise is likely in anticipation of the final approval and launch of Liquidia’s Yutrepia (treprostinil) inhalation powder in 2025, which received temporary FDA approval in 2023. Subject to final approval, the drug will be indicated for treating patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
This company is expected to post quarterly loss of $0.39 per share in its upcoming report, which represents a year-over-year change of +7.1%. Revenues are expected to be $5.13 million, up 13.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Liquidia Technologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on LQDA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Liquidia Technologies is part of the Zacks Medical - Biomedical and Genetics industry. Puma Biotech (PBYI), another stock in the same industry, closed the last trading session 0.3% higher at $2.98. PBYI has returned 5.7% in the past month.
For Puma Biotech , the consensus EPS estimate for the upcoming report has changed +50% over the past month to $0.14. This represents a change of -54.8% from what the company reported a year ago. Puma Biotech currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Liquidia Technologies, Inc. (LQDA) : Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.